SAGE PRO

Home / Research / Emmvee Photovoltaic Power Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Emmvee Photovoltaic Power Limited — Q2 FY27 Results Analysis

Operating revenue grew year on year

Published · Quarter Q2 FY27 · EMMVEE

PeriodQ2 FY27
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Q2 operating revenue

Q2 FY26₹11,310 million
Q2 FY27₹15,764 million

https://www.bseindia.com/xml-data/corpfiling/AttachHis/101db260-4a66-4957-8e53-b0278a88bade.pdf

CHART 2

H1 operating revenue

H1 FY26₹21,588 million
H1 FY27₹31,319 million

https://www.bseindia.com/xml-data/corpfiling/AttachHis/101db260-4a66-4957-8e53-b0278a88bade.pdf

CHART 3

Q2 PAT

Q2 FY26₹2,379 million
Q2 FY27₹3,820 million

https://www.bseindia.com/xml-data/corpfiling/AttachHis/101db260-4a66-4957-8e53-b0278a88bade.pdf

CHART 4

H1 PAT

H1 FY26₹4,255 million
H1 FY27₹7,623 million

https://www.bseindia.com/xml-data/corpfiling/AttachHis/101db260-4a66-4957-8e53-b0278a88bade.pdf

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Operating revenue grew year on year

Expansion must preserve returns

Watch: Monitor gross profit

RESEARCH INSIGHT

Half-year sales rose about 45%

Cash conversion matters during capex

Watch: Track collections

RESEARCH INSIGHT

Q2 PAT increased sharply

Profit is not free cash flow

Watch: Reconcile capex

RESEARCH INSIGHT

H1 PAT increased 79%

Earnings face new depreciation after commissioning

Watch: Track sustainability

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

Emmvee Photovoltaic Power Limited (EMMVEE) | Q2 and H1 FY2027 | Quarter ended 30 September 2026 | Issuer-reported financials

Investment stance: WATCH. Emmvee delivered strong year-on-year earnings growth in solar modules and cells, while pursuing a large integrated manufacturing expansion. The principal investment question is whether the company can retain attractive manufacturing margins, utilise new cell and module capacity, and fund further upstream integration without weakening cash returns. The Q2 investor presentation reports ₹15,764 million revenue from operations, ₹5,569 million EBITDA, and ₹3,820 million PAT. H1 operating revenue was ₹31,319 million, versus ₹21,588 million a year earlier, and H1 PAT was ₹7,623 million, versus ₹4,255 million. [S1][S2]

The company reported a September 10.4 GW order book, with 1.5 GW of new Q2 orders, and plans to expand installed module capacity to 16.3 GW and cell capacity to 8.9 GW by FY27-end. These are not current realised capacities. The management call discusses a ₹5,500 crore integrated module-and-cell project, with roughly ₹4,600 crore hard costs, while the presentation reports 0.12x net debt/equity at 30 September. The apparent strength of earnings must therefore be weighed against capital intensity and construction risk. [S1][S2]

Reported financial metric (₹ million)Q2 FY26Q1 FY27Q2 FY27H1 FY26H1 FY27
Revenue from operations11,31015,55515,76421,58831,319
Total income11,49415,72015,78921,91631,509
Profit after tax2,3793,8033,8204,2557,623
Gross profit5,3626,7736,69210,04613,465

The financial table uses issuer-reported amounts from the Q2 presentation. The company also presents Q2 EBITDA of ₹5,569 million and EBITDA margin 35.3%. Do not substitute gross profit for EBITDA or treat planned capacity as installed. [S2]

Six decision takeaways

  • Operating growth: Q2 revenue from operations increased approximately 39% year on year to ₹15,764 million. [S2]
  • Half-year scale: H1 revenue increased about 45% to ₹31,319 million, according to the issuer's comparison. [S2]
  • Earnings: Q2 PAT rose to ₹3,820 million from ₹2,379 million; H1 PAT rose to ₹7,623 million from ₹4,255 million. [S2]
  • Gross margin: Q2 gross profit of ₹6,692 million on ₹15,764 million operating revenue implies about 42.5%, versus roughly 47.4% a year earlier, calculated from rounded figures. [S2]
  • Capacity: The current installed footprint in the presentation is 10.3 GW modules and 2.94 GW TOPCon cells; the FY27 targets are 16.3 GW and 8.9 GW, respectively. [S1][S2]
  • Capital allocation: Management clarified that the ₹5,500 crore integrated expansion includes approximately ₹4,600 crore hard cost, with the balance for construction interest, contingency and working-capital-related soft costs. [S1]

Valuation discipline: No live share price, market capitalisation, discounted cash-flow model or normalised cycle margin has been established from these sources. The investment case should be valued against cash returns on incremental cell/module capacity, not by extrapolating current margins into perpetuity. The solar value chain faces price, technology, tariff and utilisation risks.

Chapter 1 — Investor decision and the integration thesis

Emmvee is an integrated solar photovoltaic module and TOPCon cell manufacturer with a long operating history in modules and more recent expansion into cell manufacturing. Its production footprint is concentrated within approximately 100 kilometres, and the company positions itself to supply Indian domestic-content-requirement (DCR) demand and broader solar projects. The operating strategy is to manufacture both modules and cells and progressively integrate further upstream into ingots and wafers. [S2]

The business has meaningful current scale: 10.3 GW installed module capacity and 2.94 GW installed TOPCon cell capacity are identified in the presentation. The planned expansion would lift these to 16.3 GW and 8.9 GW by FY27-end. The two stages do not have identical practical utilisation: management emphasised that cell production can run at higher sustained utilisation while module lines need flexibility for customer specifications and configurations. Consequently, simply dividing module shipments by nameplate capacity can understate the economics of a deliberately flexible module footprint. [S1][S2]

The thesis is attractive if integration protects supply, quality and DCR economics while increasing reliable deliveries. It becomes less attractive if new lines are commissioned into weak realisations, technology changes or underutilised assets. The presentation reports 89% cell utilisation and 44% module utilisation in its operational discussion. Those rates are not directly interchangeable because manufacturing stages have different scheduling constraints; investors should still monitor actual cell/module output and conversion margins. [S2]

The company also proposes a further 9 GW ingot-and-wafer initiative in two phases of 5 GW and 4 GW. Management described timing as dependent on policy and demand. It is a strategic option and planned capex, not an operating facility or revenue contributor in Q2. [S1]

Decision questions

  • Can new cells be produced and sold profitably after full commissioning costs? [S1]
  • Does integrated production sustain gross margin as industry module and cell pricing changes? [S2]
  • Will higher capacity translate into cash generation rather than only a larger revenue base?
  • Does DCR demand support premium realisations without creating excessive policy dependence? [S1]

Chapter 2 — Q2/H1 earnings and quality of profitability

The Q2 presentation reports ₹15,764 million revenue from operations, versus ₹11,310 million in Q2 FY26 and ₹15,555 million in Q1 FY27. Total income including other income was ₹15,789 million, compared with ₹11,494 million a year earlier. The distinction matters because the headline Q2 result snapshot uses total revenue of ₹15,789 million while the statutory-style operating revenue line is ₹15,764 million. This report preserves both labels. [S2]

Reported Q2 PAT increased to ₹3,820 million, versus ₹2,379 million a year earlier and ₹3,803 million sequentially. H1 PAT was ₹7,623 million against ₹4,255 million in H1 FY26. The issuer describes approximately 60.6% Q2 year-on-year PAT growth and 79% H1 growth. The presentation's Q2 EBITDA was ₹5,569 million, with margin 35.3%, and management said H1 EBITDA was about ₹1,105 crore with margins near 35%. These are the company's reported EBITDA descriptions; no unsupported normalised EBITDA adjustment is inserted. [S1][S2]

Gross profit tells a more nuanced story. Q2 gross profit increased to ₹6,692 million from ₹5,362 million, but the gross-profit ratio calculated against operating revenue declined to approximately 42.5% from 47.4%. Sequentially, gross profit was below Q1's ₹6,773 million despite slightly higher operating revenue. The presentation reports a rounded Q2 gross margin near 42%, against 47% a year earlier. Investors should not confuse EBITDA margin resilience with a lack of pressure in input economics. [S2]

The company reported H1 gross profit of ₹13,465 million versus ₹10,046 million. H1 revenue rose more rapidly than gross profit, consistent with pressure in the manufacturing gross-margin line even as scale expanded. The effect of module/cell selling prices, raw-material inputs, vertical integration and product mix needs to be tracked rather than attributing the full difference to one factor without a bridge. [S2]

Earnings-quality tests

  • Keep revenue from operations distinct from total income; Q2 other income was only ₹25 million in the presented P&L. [S2]
  • Report gross profit, EBITDA and PAT as separate levels of earnings. [S2]
  • Do not manufacture adjusted PAT when the source pair does not support a specific adjustment.
  • Compare sequential and year-on-year figures because Q2 PAT growth was strong year on year but almost flat versus Q1. [S2]

Chapter 3 — Module and cell economics, orders and customer demand

Emmvee's module business serves utility-scale and other solar demand, while the cell operation strengthens the domestic-content and supply-chain proposition. The presentation describes TOPCon cell manufacturing and integration into high-reliability module products. Management views the ALMM List-II framework and DCR rules as supportive of local manufacturing. Regulatory support can protect addressable demand, but it also makes the earnings thesis sensitive to implementation details and policy changes. [S1][S2]

The September order book was presented as 10.4 GW, with 1.5 GW of new orders during Q2. The company also described a stronger pipeline and larger utility demand from firm/dispatchable renewable energy and round-the-clock procurement, which can require battery storage and more solar DC capacity. These are demand drivers, not automatic future sales or margins. Investors should separate firm orders, negotiated orders and prospective tenders. [S1][S2]

The presentation identifies 10.3 GW existing module manufacturing capacity and 2.94 GW existing TOPCon cell capacity. Management expects new integrated capacity to be commissioned in stages: module expansion around December 2026, followed by cell capacity around March 2027. The timing is forward-looking and should be verified in later disclosures. The capacity targets of 16.3 GW modules and 8.9 GW cells should not appear in a chart labelled actual September installed capacity. [S1][S2]

Management argued that modules and cells require different practical utilisation rates. This is economically plausible because module lines accommodate product variation while cell lines are designed for more continuous throughput. The reported 89% cell utilisation and 44% module utilisation are therefore important operating observations, but investors should still seek realised output, yield, scrap, energy consumption and gross profit by manufacturing stage. [S2]

Operating takeaways

  • Watch actual module and cell commissioning dates against management's timetable. [S1]
  • Require disclosure of firm orders and deliveries separately from negotiated opportunities. [S1][S2]
  • Monitor gross profit per watt, if disclosed, rather than relying only on sales growth.
  • Track customer and DCR-policy exposure, especially if the supply/demand balance shifts.
  • Separate current 10.3/2.94 GW capacity from planned 16.3/8.9 GW capacity. [S2]

Chapter 4 — Management execution and analyst Q&A

The October earnings call emphasised vertical integration, manufacturing scale and regulatory positioning. Management described the integrated 6 GW module-and-cell project as on track, with module commissioning expected before cell commissioning. It also said the future capacity mix was designed around the different operating characteristics of cells and modules rather than identical nameplate utilisation. These explanations are operationally meaningful, but only actual commissioning, output and cash margin will confirm the strategy. [S1]

An analyst challenged the expansion's capital cost, comparing management's roughly ₹5,500 crore integrated project estimate with lower industry cost estimates. Management clarified that the figure covers both cell and module capacity and includes about ₹4,600 crore of hard cost; the remainder includes construction interest, contingencies, working-capital margin and other soft costs. The appropriate comparison is therefore a like-for-like integrated project cost, not a cell-equipment-only benchmark. [S1]

The presentation also discusses an upstream ingot-and-wafer project, estimated at approximately ₹5,000–5,500 crore, with the aim of protecting DCR economics and upstream supply. That is distinct from the ongoing integrated cell/module project, and the report does not add their capacity or cost as though both had already been commissioned. Management said further upstream timing would depend on market and regulatory development. [S1][S2]

The policy discussion matters. Management highlighted ALMM List-II inclusion for G12R TOPCon cells and the continuing domestic-content framework. Solar manufacturing is exposed to both policy support and price competition. A rule change, delayed customer project or rapid technology transition could affect the return on assets built to serve the current domestic demand structure. [S1][S2]

Execution checklist

  • Confirm December module and March cell commissioning against actual disclosures. [S1]
  • Reconcile project cost and funding sources with the final asset register and cash-flow statement. [S1]
  • Track output, yields and customer deliveries following commissioning.
  • Distinguish the proposed upstream 9 GW plan from the 6 GW integrated project under execution. [S1][S2]

Chapter 5 — Cash, leverage, capex and payback

The company reports net debt/equity of 0.12x as of 30 September 2026 in its result snapshot. This is a ratio, not an absolute net-debt amount, and the presentation's ratio cannot by itself be converted into rupees without a consistent equity and debt reconciliation. The company has reported strong profitability, but capacity expansion is capital-intensive and can absorb substantial cash before lines generate commercial output. [S2]

The cash-flow statement in the presentation reports H1 FY27 ₹11,118 million cash outflow for purchases of property, plant and equipment, including capital work in progress and capital advances. The FY26 comparator for this line is ₹6,531 million for the full financial year; it should not be described as an H1 FY26 comparator. The presentation also reports H1 FY27 operating profit before working-capital changes of ₹11,113 million. Those two numbers illustrate why working capital, capex phasing and funding matter, but they are not a complete free-cash-flow calculation. [S2]

The integrated expansion project has an estimated ₹5,500 crore total cost, of which approximately ₹4,600 crore is hard cost, as clarified in Q&A. Management discussed project debt of roughly ₹3,300 crore in the presentation's funding discussion. These are planned project economics and financing figures, not a statement that all amounts were drawn or spent by September. [S1][S2]

The proposed ingot-and-wafer project adds another potential ₹5,000–5,500 crore commitment. Management expects to fund much of that through internal accruals, subject to timing. The risk is not simply the nominal capex number: it is the possibility of falling cell/module realisations, slower utilisation or new technology requiring additional investment before the first expansion earns its cost of capital. [S1][S2]

The balance-sheet case should be assessed through cash from operations after receivables and inventory movements, cash capex, borrowing drawdowns, interest and commissioning milestones. A low net-debt/equity ratio today does not eliminate funding risk from future investments. Conversely, productive integrated assets could improve supply security and margins if demand and pricing remain supportive.

Capital tests

  • Track actual H2 cash capex separately from announced project budgets. [S2]
  • Reconcile drawn debt to the ₹3,300 crore project-financing discussion. [S1][S2]
  • Compare commissioning dates with first commercial shipments and cash collections.
  • Require investment returns on new cell capacity before assuming further upstream investment is value accretive.
  • Do not equate strong EBITDA with free cash flow while major projects are under construction.

Chapter 6 — Bull, base and bear cases with falsifiers

Bull case — integration sustains margins. The module and cell expansions commission on time, ramp efficiently and support higher domestic-content sales. The company maintains attractive EBITDA margins as more orders convert into production, and internally generated cash helps finance the next integration phase. The thesis strengthens if gross profit per unit stabilises, utilisation increases and leverage remains manageable after full capex. These are conditional outcomes, not forecasts.

Base case — growth continues but margins normalise. The order book supports revenue, but gross margin remains below the prior-year level as input prices, product mix and competition change. New facilities require ramp-up time and additional working capital. The company remains profitable while cash returns lag accounting earnings during construction. The investment case stays sensitive to the pace of commissioning and the ability to finance upstream projects.

Bear case — overcapacity and policy change impair returns. Domestic or global supply rises faster than demand, selling prices weaken, and new cell/module assets operate below economic utilisation. The company commits substantial capital to integration just as technology or policy shifts require further investment. Financing and depreciation costs could then pressure shareholder returns despite high nominal installed capacity.

Falsifiers

  • Q2 gross margin near 42% declines further without a clear cost or mix explanation. [S2]
  • Planned module or cell commissioning is materially delayed. [S1]
  • The 10.4 GW September order book fails to convert into shipments on acceptable terms. [S2]
  • The 0.12x net-debt/equity ratio rises sharply as project funding is drawn. [S2]
  • The proposed ingot-and-wafer expansion proceeds without clear demand, cost and financing discipline. [S1][S2]
  • EBITDA margins weaken materially from the disclosed Q2 35.3% level. [S2]

No unsupported price target, terminal multiple or promised future ROIC is assigned.

Chapter 7 — Investor action plan and monitoring

Action: WATCH pending evidence of sustainable manufacturing economics and cash-funded expansion. Emmvee has demonstrated strong Q2 and H1 profit growth, but a substantial new asset base is approaching commissioning. The next two quarters should establish whether high margins and domestic orders are durable enough to earn acceptable returns on the investment programme.

Monitoring itemLatest sourced figureNext decision test
Q2 operating revenue₹15,764 millionGrowth and realisation quality
Q2 EBITDA₹5,569 millionMaintain margin after capacity expansion
Q2 PAT₹3,820 millionEarnings versus cash generation
Q2 gross profit₹6,692 millionGross margin and input-price sensitivity
H1 operating revenue₹31,319 millionH2 order conversion
H1 PAT₹7,623 millionSustainability after new depreciation
Order book10.4 GW at SeptemberFirm orders, dispatches and receipts
Existing module capacity10.3 GWActual output and utilisation
Existing cell capacity2.94 GWRamp and product yields
FY27 planned capacities16.3 GW modules; 8.9 GW cellsCommissioning dates and unit economics
Net debt/equity0.12xDebt drawdowns and equity returns
H1 PPE/CWIP/advances cash outflow₹11,118 millionActual capex and funding
Integrated expansion costAbout ₹5,500 crore plannedFinal cost and commercial payback

Quarterly monitoring checklist

  • Reconcile operating revenue and total income rather than treating the two as identical. [S2]
  • Compare gross profit, EBITDA and PAT margins on a consistent reported basis. [S2]
  • Validate actual installed module/cell capacity and production against the commissioning schedule. [S1][S2]
  • Track orders and negotiated pipeline separately, including cancellations and delivery milestones. [S1][S2]
  • Reconcile operating cash flow, inventory, receivables and capital expenditure.
  • Distinguish planned project debt and capex from amounts already incurred. [S1]
  • Monitor ALMM/DCR policy and cell/module technology developments. [S1][S2]

Specific evidence limitations: The accepted source pair supports issuer-reported operating metrics and a published cash-flow statement, but this report does not reconstruct a complete future project-by-project free-cash-flow or return-on-invested-capital model. Planned FY27 capacity, upstream projects and financing are forward-looking, while September installed capacity and Q2/H1 results are historical. Gross profit, EBITDA and PAT remain distinct measures.

Original issuer/exchange sources

Financial tables use ₹ million, unless specifically labelled ₹ crore; production capacity and order book use GW. Derived ratios are calculated from the issuer's presented figures.

Additional company evidence

CHART 5

Q2 gross profit

Q2 FY26₹5,362 million
Q2 FY27₹6,692 million

https://www.bseindia.com/xml-data/corpfiling/AttachHis/101db260-4a66-4957-8e53-b0278a88bade.pdf

CHART 6

H1 gross profit

H1 FY26₹10,046 million
H1 FY27₹13,465 million

https://www.bseindia.com/xml-data/corpfiling/AttachHis/101db260-4a66-4957-8e53-b0278a88bade.pdf

CHART 7

Q2 total income

Q2 FY26₹11,494 million
Q2 FY27₹15,789 million

https://www.bseindia.com/xml-data/corpfiling/AttachHis/101db260-4a66-4957-8e53-b0278a88bade.pdf

CHART 8

Operating revenue

Q1 FY27₹15,555 million
Q2 FY27₹15,764 million

https://www.bseindia.com/xml-data/corpfiling/AttachHis/101db260-4a66-4957-8e53-b0278a88bade.pdf

SOURCE REFERENCES

Original disclosures and investor presentations

  1. Issuer disclosure
  2. Issuer disclosure

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.